| Budget Amount *help |
¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 1987: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1986: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Research Abstract |
The serum levels of anti-dopaminergic (anti-D-2), anti-alpha-adrenergic and anti-serotonergic activities of neuroleptics were determined in schizophrenic patients on maintenance therapy. It was revealed that the anti-D-2 activity of neuroleptics was the most important in preventing relapses in schizophrenic patients. However, it was also revealed that serum levels of anti-D-2 activity were different among clinically equivalent doses of different neuroleptics, so serum levels of anti-D-2 activity of neuroleptics cannot be used as indicators for preventing relapses in schizophrenic patients unless their effective concentrations are determined for an individual neuroleptic. In the present study serum levels of anti-D-2 activity in patients whose conditions remained stable were evaluated for eight different neuroleptics. As a result, it was suggested that serum levels of anti-D-2 activity required to prevent relapses in schizophrenic patients might be 55-24 ng(haloperidol equivalent)/ml for thioridazine, 31-19 ng/ml for clocapramine, 33-11 ng/ml for sulpiride, 35-5 ng/ml for propericiazine, 18-9 ng/ml for levomepromazine, 13-6 mg/nl for pimozide, 14-4 mg/ml for chlorpromazine, and 7-3 ng/ml for haloperidol. Relapse rates were higher in patients whose serum levels of anti-D-2 activity were below the effective concentrations given above than patients whose serum levels were within the ranges of effective concentrations,therefore, they may justifiably be referred to as effective concentrantions required for preventing relapses in schizophrenic patients. The incidences of side effect increased with increasing serum levels of each pharmacological activity of neuroleptic. However, side effects are induced by other pharmacological activities of neuroleptics and additional medications, so it may be also necessary to determine serum levels of these pharmacological activities.
|
